EUVIMED · CrossrefZeitschrift
Blood Cancer Discovery
ISSN 2643-3230 · American Association for Cancer Research (AACR)
Neueste Artikel
Preclinical characterization of the potent and selective MALT1 inhibitor safimaltib in B-cell lymphoma models
A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T–Resistant Large B-cell Lymphomas
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP
Germline Noncoding Risk Variants Influence Clonal Hematopoiesis through Altered Hematopoietic Enhancer Activity
Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution
CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy
In Vivo CAR T-cell Therapy: Determinants of Response and Durability
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia
CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All
A (Post)translational Opportunity in RAS-Dependent Heme Malignancy
Highlighted Research Articles
Targeting MALT1 in B-cell Lymphomas
Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma
Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use
A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies
Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL
Tumor-Infiltrating Clonal Hematopoiesis Is Associated with Adverse Clinical Outcomes in Diffuse Large B-cell Lymphoma
CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles
Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T–Treated T-cell Lymphoid Malignancies
The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
EUVIMED